PMID: 15220685Jun 29, 2004Paper

Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study

Journal of Clinical Gastroenterology
George K AnagnostopoulosDimitrios Arvanitidis

Abstract

Esomeprazole has higher oral bioavailability and increased antimicrobial activity against Helicobacter pylori than omeprazole. To compare 7 days esomeprazole with 7 days of omeprazole based triple therapies for the eradication of H. pylori, and to assess whether the administration of higher dose of esomeprazole leads to improved eradication rates. One hundred and fifty-six dyspeptic patients with H. pylori received either: (1) 1-week treatment including esomeprazole 40 mg once daily, amoxicillin 1 g, and clarithromycin 500 mg, both twice daily (EAC1 group, n = 52); (2) 1-week treatment of omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, all administered twice daily (OAC group, n = 52); or (3) 1-week treatment with esomeprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily (EAC2 group, n = 52). H. pylori was eradicated in 37 of 52 patients in the OAC group (Intension to treat [ITT] 71%), and in 42 patients in the EAC1 group (ITT 81%). High eradication rate was achieved by the EAC2 regimen (ITT; 96%), but more patients reported unwanted effects. Seven days of esomeprazole based triple therapy is a satisfactory eradication regimen for H. pylori infection. Higher doses of esomeprazole have ex...Continue Reading

References

Sep 13, 2000·Drugs·C M Spencer, D Faulds
Dec 21, 2000·Alimentary Pharmacology & Therapeutics·S Veldhuyzen Van ZantenP Sinclair
Jul 28, 2001·Clinical Pharmacokinetics·T AnderssonL Weidolf
Aug 2, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P N MatonUNKNOWN Esomeprazole Study Investigators
Sep 21, 2001·Alimentary Pharmacology & Therapeutics·T AnderssonM Hassan-Alin
Feb 4, 2003·The Journal of Antimicrobial Chemotherapy·Luigi GattaDino Vaira
Jun 6, 2003·Alimentary Pharmacology & Therapeutics·F Mégraud, H Lamouliatte

❮ Previous
Next ❯

Citations

Aug 19, 2006·Expert Opinion on Investigational Drugs·Andrea MorgnerStephan Miehlke
Sep 24, 2005·Helicobacter·Peter Bytzer, Colm O'Morain
May 17, 2006·Alimentary Pharmacology & Therapeutics·C Scarpignato, I Pelosini
Aug 19, 2007·European Journal of Clinical Investigation·P I HsuG H Lo
Nov 18, 2015·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Waheed AsgharFakhreddin Jamali
Mar 8, 2018·Helicobacter·Wen Zhong LiuUNKNOWN Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer
Feb 25, 2014·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Yeoun Su JungChang Heon Yang
Jul 17, 2010·Helicobacter·Chao-Hung KuoDeng-Chyang Wu
Sep 17, 2019·Therapeutic Advances in Gastroenterology·Chia-Jung KuoCheng-Tang Chiu
Feb 3, 2009·Alimentary Pharmacology & Therapeutics·A Sachdeva, J Nagpal
May 23, 2017·Frontiers in Cellular and Infection Microbiology·Yi HuNong-Hua Lu
Sep 29, 2019·World Journal of Gastroenterology : WJG·Enzo IerardiAlfredo Di Leo
Jan 11, 2013·Journal of Digestive Diseases·UNKNOWN Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pyloriPin Jin Hu
Jul 13, 2021·International Journal of Immunopathology and Pharmacology·Wenwen GaoLu Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.